
Nawab Qizilbash

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/933253/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------------------|---------------------|
| 1 | Body-mass index and cause-specific mortality in 900â€^000 adults: collaborative analyses of 57 prospective studies. Lancet, The, 2009, 373, 1083-1096. | 13.7 | 3,779 |
| 2 | BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2015, 3, 431-436. | 11.4 | 343 |
| 3 | Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiology and Drug Safety, 2007, 16, 485-492. | 1.9 | 93 |
| 4 | Association of anthropometry and weight change with risk of dementia and its major subtypes: A metaâ€analysis consisting 2.8 million adults with 57 294 cases of dementia. Obesity Reviews, 2020, 21, e12989. | 6.5 | 62 |
| 5 | Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study. The Lancet Healthy Longevity, 2021, 2, e498-e506. | 4.6 | 53 |
| 6 | Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU International, 2008, 102, 981-986. | 2.5 | 43 |
| 7 | A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Postâ€Authorization Studies. Pharmacoepidemiology and Drug Safety, 2018, 27, 695-706. | 1.9 | 30 |
| 8 | Benefit–Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis. Clinical Therapeutics, 2012, 34, 159-176.e5. | 2.5 | 26 |
| 9 | A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada. Canadian Respiratory Journal, 2016, 2016, 1-10. | 1.6 | 23 |
| 10 | Risk of ischaemic cardiovascular events from selective cyclooxygenaseâ€2 inhibitors in osteoarthritis. Pharmacoepidemiology and Drug Safety, 2008, 17, 601-608. | 1.9 | 21 |
| 11 | Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opinion on Drug Safety, 2019, 18, 443-454. | 2.4 | 21 |
| 12 | Localised neuropathic pain in the primary care setting: a cross-sectional study of prevalence, clinical characteristics, treatment patterns, quality of life and sleep performance. Current Medical Research and Opinion, 2021, 37, 293-302. | 1.9 | 8 |
| 13 | Raised blood pressure and risk of dementia. European Heart Journal, 2019, 40, 785-786. | 2.2 | 5 |
| 14 | Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept () Tj ETQq0 0 C Safety, 2020, 29, 664-674. | rgBT /Ove 1.9 | rlock 10 Tf 50 3 |
| 15 | Does midlife obesity really lower dementia risk? – Authors' reply. Lancet Diabetes and Endocrinology,the, 2015, 3, 501-502. | 11.4 | 2 |
| 16 | Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. Pharmacoepidemiology and Drug Safety, 2020, 29, 103-110. | 1.9 | 2 |
| 17 | Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink. Current Medical Research and Opinion, 2022, , 1-8. | 1.9 | 0 |
| 18 | Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union. Pharmaceutical Medicine, 2021, 35, 339-351. | 1.9 | 0 |